DILIsym Services

A SIMULATIONS PLUS COMPANY

www.dilisym.com

(NASDAQ: SLP)



DILIsym is Quantitative Systems Toxicology (QST) software capable of **predicting** and **explaining** Drug-Induced Liver Injury (DILI)

Sound Science

- Developed through The DILI-sim Initiative, a consortium supported by 17 pharmaceutical companies and the FDA; regularly updated to include leading edge science
- Includes interacting sub-models such as: PBPK sub-model of drug disposition; bile acid representation of homeostasis and disruption by transporter inhibition; mitochondrial function and dysfunction sub-model including lipid metabolism and lipotoxicity; sub-model of oxidative stress generation and clearance; cell death representation of hepatocyte apoptosis, necrosis, and regeneration; representations of many well-accepted and novel biomarkers of liver injury
- Many publications released describing design and applications

Capable

- Utilizes compound-specific *in vitro* data to enable predictions
- Humans, rats, mice and dogs included
- SimPops™ incorporate inter-individual physiological variability
- User-friendly GUI for *in silico* experiments and visualization of results



Application Driven

- Rank candidates for DILI potential
- Extrapolate from animal and in vitro findings to humans
- Optimize clinical dose (risk versus presumed benefit)
- Infer magnitude of injury based on measured biomarkers
- Extrapolate from healthy volunteers to patient groups
- Guide incorporation of emerging biomarker measurements in clinical trials
- Analyze mechanisms underlying observed liver signals
- Inform choice and timing of biomarker measurements
- Aid identification of risk factors leading to precision medicine approaches

DILIsym Services:
+1-919-558-1323
info@dilisym.com

Simulations Plus:
+1-661-723-7723
info@simulations-plus.com

Cognigen:
+1-716-633-3463
info@cognigencorp.com

Rev. 10/10/17